Brought to you by 
Celladon brings in $43mm through its Series D venture round; adds $10mm
25 Jun 2012
Executive Summary
Celladon Corp. has raised $43mm through what appears to be its Series D venture round. Pfizer Venture Investments led and was joined by fellow new investors Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners, and all returning shareholders, including JEnterprise Partners Venture Capital, Johnson & Johnson Development Corp., and Venrock Associates. Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Capital Management, and GBS Venture Partners will each add one member to Celladon's board. The company is developing Phase II Mydicar for advanced heart failure with Targeted Genetics under a 2005 deal.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celladon brings in $43mm through its Series D venture round; adds $10mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice